Reference

CEM_CMO(2021)014

Name

COVID therapeutic alert – Pavilizumab passive immunisation against respiratory syncytial virus (RSV) in pre-term infants

Categories

Scottish Government CMO Letters

Organization

Scottish Government Health and Social Care Directorates

Keywords

NHS SCOTLAND COVID-19 CORONAVIRUS TREATMENTS DRUGS IMMUNISATION RESPIRATORY SYNCYTIAL VIRUS RSV PATIENTS HOSPITALS

Description

Palivizumab is a humanised monoclonal antibody. It offers a form of passive immunisation, effectively providing short-term protection against RSV and reducing the risk of hospitalisation. The updated UK rapid policy statement, which extends eligibility for palivizumab beyond the guidance issued by the Joint Committee on Vaccination and Immunisation (JCVI), specifically in the context of the COVID-19 pandemic, has now been updated to accommodate the atypical current seasonal pattern of infection and increase the maximum number of doses from five to seven.

Contact Name

Irene Fazakerley

Contact Email

Contact Address

Chief Medical Officer Directorate Pharmacy and Medicines Division St Andrew’s House Regent Road Edinburgh EH1 3DG

Contact Phone

Created

2021-07-28 00:00:00

Download URL